Phosphoinositide 3-kinases as targets for therapeutic intervention

被引:78
作者
Wetzker, R
Rommel, C
机构
[1] Univ Jena, D-07747 Jena, Germany
[2] Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland
关键词
PI; 3-kinase; target; inhibitor; signal transduction; cancer; inflammation;
D O I
10.2174/1381612043384402
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Phosphoinositide 3-kinases (PI3K) represent a family of intracellular signaling proteins, which control a variety of important cellular functions such as proliferation, apoptosis and migration. Recent findings suggest an involvement of PI3K in the pathogenesis of numerous diseases including cancer, heart failure and autoimmune/inflammatory disorders. This review summarizes the current knowledge of the emerging therapeutic value of PI3K as targets for the intervention of several pathological disorders and in particular focusing on oncogenesis. A brief introduction on the molecular and biochemical features of these signaling proteins will be followed by a depiction of signaling interactions of PI3K in a cellular context. PI3K dependent signaling involved in the control of cell growth, proliferation, survival and cytoskeletal remodeling and the link to cellular dysfunctions will be discussed. Further we will summarize the phenotypic consequences by genetic targeting PI3K signaling in mice. In its final part this review outlines challenges and activities considering PI3K as targets for therapeutic intervention and progress in the development of first generation small molecule inhibitors.
引用
收藏
页码:1915 / 1922
页数:8
相关论文
共 53 条
[1]   Mechanism of activation of protein kinase B by insulin and IGF-1 [J].
Alessi, DR ;
Andjelkovic, M ;
Caudwell, B ;
Cron, P ;
Morrice, N ;
Cohen, P ;
Hemmings, BA .
EMBO JOURNAL, 1996, 15 (23) :6541-6551
[2]   Signal transduction pathways activated and required for mammary carcinogenesis in response to specific oncogenes [J].
Amundadottir, LT ;
Leder, P .
ONCOGENE, 1998, 16 (06) :737-746
[3]   Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110α subunit of phosphoinositide 3-kinase [J].
Bi, L ;
Okabe, I ;
Bernard, DJ ;
Wynshaw-Boris, A ;
Nussbaum, RL .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (16) :10963-10968
[4]   Early embryonic lethality in mice deficient in the p110β catalytic subunit of PI 3-kinase [J].
Bi, L ;
Okabe, I ;
Bernard, DJ ;
Nussbaum, RL .
MAMMALIAN GENOME, 2002, 13 (03) :169-172
[5]   Differential regulation of lipid and proteins kinase activities of phosphoinositide 3-kinase γ in vitro [J].
Bondev, A ;
Rubio, I ;
Wetzker, R .
BIOLOGICAL CHEMISTRY, 1999, 380 (11) :1337-1340
[6]   Bifurcation of lipid and protein kinase signals of PI3Kγ to the protein kinases PKB and MAPK [J].
Bondeva, T ;
Pirola, L ;
Bulgarelli-Leva, G ;
Rubio, I ;
Wetzker, R ;
Wymann, MP .
SCIENCE, 1998, 282 (5387) :293-296
[7]   Receptor tyrosine kinases as target for anti-cancer therapy [J].
Brunelleschi, S ;
Penengo, L ;
Santoro, MM ;
Gaudino, G .
CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (22) :1959-1972
[8]   Transformation of chicken cells by the gene encoding the catalytic subunit of PI 3-kinase [J].
Chang, HW ;
Aoki, M ;
Fruman, D ;
Auger, KR ;
Bellacosa, A ;
Tsichlis, PN ;
Cantley, LC ;
Roberts, TM ;
Vogt, PK .
SCIENCE, 1997, 276 (5320) :1848-1850
[9]  
Clark AS, 2002, MOL CANCER THER, V1, P707
[10]   Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways [J].
Crackower, MA ;
Oudit, GY ;
Kozieradzki, I ;
Sarao, R ;
Sun, H ;
Sasaki, T ;
Hirsch, E ;
Suzuki, A ;
Shioi, T ;
Irie-Sasaki, J ;
Sah, R ;
Cheng, HYM ;
Rybin, VO ;
Lembo, G ;
Fratta, L ;
Oliveira-dos-Santos, AJ ;
Benovic, JL ;
Kahn, CR ;
Izumo, S ;
Steinberg, SF ;
Wymann, MP ;
Backx, PH ;
Penninger, JM .
CELL, 2002, 110 (06) :737-749